Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 11/20 | 0.41 |
| ▸ | RAF1 | P04049 | 1/20 | 0.34 |
| ▸ | BRAF | P15056 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 4/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 2/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | RET | P07949 | 1/20 | 0.33 |
| ▸ | KIF5B | P33176 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9728955 | 0.90 | EGFR (0.43) | EGFRKRASSOS1CNR1CNR2 | |
| SCHEMBL9279868 | 0.83 | EGFR (0.38) | EGFRKRASSOS1CNR1CNR2 | |
| SCHEMBL9728970 | 0.81 | EGFR (0.40) | EGFRKRASSOS1CNR1CNR2 | |
| SCHEMBL8014129 | 0.76 | EGFR (0.43) | EGFRKRASSOS1RPS6KB1RET | |
| SCHEMBL9729028 | 0.76 | EGFR (0.41) | EGFRKRASSOS1CNR1CNR2 | |
| SCHEMBL8024922 | 0.75 | EGFR (0.42) | EGFRKRASSOS1CNR1CNR2 | |
| SCHEMBL11102122 | 0.74 | CNR1 (0.47) | EGFRCNR1CNR2P2RX3 | |
| SCHEMBL11099038 | 0.74 | EGFR (0.45) | EGFRKRASSOS1CNR1CNR2 | |
| SCHEMBL8755978 | 0.72 | GALR3 (0.41) | EGFRKRASSOS1CNR1CNR2 | |
| SCHEMBL8025127 | 0.72 | EGFR (0.46) | EGFRKRASSOS1RPS6KB1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9447081-B2 | Substituted pyrimidines as pharmaceuticals and insecticides | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2016-09-20 | — | — | US | disclosed |
| US-9447081-B2 | Substituted pyrimidines as pharmaceuticals and insecticides | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2016-09-20 | — | — | US | disclosed |
| US-20150225378-A1 | HOMOPIPERONY LAMINE COMPOUND AND USE THEREOF | SINOCHEM CORPORATION (CN) | 2015-08-13 | — | — | US | disclosed |
| US-20150225378-A1 | HOMOPIPERONY LAMINE COMPOUND AND USE THEREOF | SINOCHEM CORPORATION (CN) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225378-A1 | HOMOPIPERONY LAMINE COMPOUND AND USE THEREOF | CLPP, LRRK2, MYB | EGFR 4778/4885RAF1 3582/4885BRAF 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.